PRM 151

Drug Profile

PRM 151

Alternative Names: PRM-151; rhPTX 2; rhSAP; SAP; Serum amyloid P

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Promedior
  • Class Anti-inflammatories; Antifibrotics; Glycoproteins; Recombinant proteins
  • Mechanism of Action Cell differentiation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scars; Myelofibrosis; Idiopathic pulmonary fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Myelofibrosis; Scars
  • Preclinical Lung disorders
  • No development reported Kidney disorders

Most Recent Events

  • 02 Dec 2016 Promedior completes enrolment in the phase II trial for Idiopathic pulmonary fibrosis in USA, Netherland, Germany, Belgium, Czech Republic, Spain, Italy, Switzerland and Hungary (NCT02550873) (EudraCT2014-004782-2)
  • 02 Dec 2016 Promedior completes enrolment in the phase II trial for Myelofibrosis in USA and Canada (NCT01981850)
  • 26 Oct 2016 Phase-II clinical trials in Idiopathic pulmonary fibrosis in USA, Italy and Switzerland (IV) (NCT02550873)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top